Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.39 |
| ▸ | SELE | P16581 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23109901 | 1.00 | ROCK2 (0.52) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL23501200 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL30744167 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL23501202 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL23109896 | 0.89 | ROCK2 (0.51) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL24845606 | 0.89 | ROCK2 (0.51) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL23109894 | 0.82 | ROCK2 (0.64) | ROCK2ROCK1MYLK4 | |
| SCHEMBL23501330 | 0.82 | ROCK2 (0.64) | ROCK2ROCK1MYLK4 | |
| SCHEMBL23501276 | 0.82 | ROCK2 (0.49) | ROCK2ROCK1MYLK4ICAM1SELE | |
| SCHEMBL30744185 | 0.82 | ROCK2 (0.49) | ROCK2ROCK1MYLK4ICAM1SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002404-A1 | HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF | ALCON INC. (CH) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002404-A1 | HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF | UACA, PHKG2, CCAR2 | ROCK2 145/4885ROCK1 260/4885MYLK4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.